On September 30, XTALPI rose 5.01% in regular trading, trading at HK$8.32/share, with turnover of HK$148 million. The rally was driven by the announcement that the company's jointly developed graphite electrode intelligent raw material selection model with Fangda Carbon New Material Technology has completed full testing and project acceptance.
According to the announcement, XTALPI stated that this milestone marks the successful penetration of its AI for Science platform into complex heavy industrial manufacturing processes, directly converting AI algorithms into workshop procurement strategies and material selection lists. The company emphasized that this translates cutting-edge computing power into tangible profit margins and productivity gains for physical manufacturing.
The broader Life Sciences Tools & Services sector saw widespread gains, with GenScript Biotech up 8.16%, Insilico Intelligence up 7.40%, WuXi XDC up 4.04%, WuXi Biologics up 2.71%, and WuXi AppTec up 1.25%. XTALPI reported H1 revenue of RMB 394 million and maintains a cash balance of RMB 8.67 billion, supporting continued R&D investment across its AI4S platform.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)